Mirum Pharmaceuticals (MIRM) Competitors $74.19 -0.12 (-0.16%) Closing price 04:00 PM EasternExtended Trading$74.21 +0.02 (+0.03%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MIRM vs. ASND, VTRS, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, and RVMDShould you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Mirum Pharmaceuticals vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Ascendis Pharma A/S (NASDAQ:ASND) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends. Which has better earnings and valuation, ASND or MIRM? Mirum Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$490.75M24.28-$409.12M-$5.16-37.72Mirum Pharmaceuticals$336.89M11.06-$87.94M-$1.21-61.31 Does the media favor ASND or MIRM? In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Mirum Pharmaceuticals and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Mirum Pharmaceuticals' score of 0.48 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ASND or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -13.65% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% Mirum Pharmaceuticals -13.65%-24.76%-8.50% Do analysts rate ASND or MIRM? Ascendis Pharma A/S presently has a consensus price target of $244.36, suggesting a potential upside of 25.56%. Mirum Pharmaceuticals has a consensus price target of $74.44, suggesting a potential upside of 0.34%. Given Ascendis Pharma A/S's higher probable upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has more volatility & risk, ASND or MIRM? Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. SummaryMirum Pharmaceuticals beats Ascendis Pharma A/S on 8 of the 15 factors compared between the two stocks. Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRM vs. The Competition Export to ExcelMetricMirum PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.73B$3.10B$5.74B$10.24BDividend YieldN/A2.32%5.69%4.59%P/E Ratio-61.3121.3874.9326.41Price / Sales11.06244.04457.2789.16Price / CashN/A44.4425.8129.91Price / Book15.799.6413.256.28Net Income-$87.94M-$53.20M$3.29B$270.38M7 Day Performance-4.13%0.44%0.47%2.70%1 Month Performance9.22%4.26%4.60%5.99%1 Year Performance80.42%9.43%73.42%25.94% Mirum Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRMMirum Pharmaceuticals3.3249 of 5 stars$74.19-0.2%$74.44+0.3%+80.7%$3.73B$336.89M-61.31140Analyst ForecastInsider TradeASNDAscendis Pharma A/S3.1994 of 5 stars$205.22-0.3%$244.36+19.1%+64.0%$12.60B$393.54M-39.771,017Positive NewsVTRSViatris1.6346 of 5 stars$10.48-0.2%$10.40-0.8%-14.6%$12.24B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.2893 of 5 stars$14.27-0.5%$16.95+18.8%-8.9%$11.97B$3.81B21.6127,811News CoverageQGENQIAGEN4.4431 of 5 stars$47.62+0.1%$49.69+4.4%+0.5%$10.57B$1.98B28.135,765BBIOBridgeBio Pharma4.4155 of 5 stars$54.29+1.7%$63.35+16.7%+95.6%$10.20B$221.90M-13.27400Positive NewsAnalyst ForecastMRNAModerna4.5326 of 5 stars$24.83-1.2%$42.88+72.7%-65.6%$9.78B$3.24B-3.305,800VRNAVerona Pharma PLC American Depositary Share2.3184 of 5 stars$106.300.0%$109.00+2.5%+257.4%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.6289 of 5 stars$19.02+3.2%$17.33-8.9%+28.0%$9.16B$4.44B22.129,000Positive NewsROIVRoivant Sciences3.1565 of 5 stars$12.91-0.1%$16.38+26.8%+17.9%$8.82B$29.05M-18.44860RVMDRevolution Medicines4.1949 of 5 stars$41.06+1.4%$72.00+75.4%+6.5%$7.57B$11.58M-9.12250Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors QIAGEN Competitors BridgeBio Pharma Competitors Moderna Competitors Verona Pharma PLC American Depositary Share Competitors Elanco Animal Health Competitors Roivant Sciences Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRM) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
